These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 25330687)

  • 1. Role of the combination spironolactone-norgestimate-estrogen in Hirsute women with polycystic ovary syndrome.
    Hagag P; Steinschneider M; Weiss M
    J Reprod Med; 2014; 59(9-10):455-63. PubMed ID: 25330687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spironolactone as a single agent for long-term therapy of hirsute patients.
    Spritzer PM; Lisboa KO; Mattiello S; Lhullier F
    Clin Endocrinol (Oxf); 2000 May; 52(5):587-94. PubMed ID: 10792338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the clinical efficacy of flutamide and spironolactone plus ethinyloestradiol/cyproterone acetate in the treatment of hirsutism: a randomised controlled study.
    Karakurt F; Sahin I; Güler S; Demirbas B; Culha C; Serter R; Aral Y; Bavbek N
    Adv Ther; 2008 Apr; 25(4):321-8. PubMed ID: 18389188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of desogestrel/ethinyl estradiol plus spironolactone versus cyproterone acetate/ethinyl estradiol in the treatment of polycystic ovary syndrome: a randomized controlled trial.
    Leelaphiwat S; Jongwutiwes T; Lertvikool S; Tabcharoen C; Sukprasert M; Rattanasiri S; Weerakiet S
    J Obstet Gynaecol Res; 2015 Mar; 41(3):402-10. PubMed ID: 25319761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral contraceptive plus antiandrogen therapy and cardiometabolic risk in polycystic ovary syndrome.
    Harmanci A; Cinar N; Bayraktar M; Yildiz BO
    Clin Endocrinol (Oxf); 2013 Jan; 78(1):120-5. PubMed ID: 22702394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of four different treatment regimes in hirsutism related to polycystic ovary syndrome.
    Gökmen O; Senöz S; Gülekli B; Işik AZ
    Gynecol Endocrinol; 1996 Aug; 10(4):249-55. PubMed ID: 8908525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome.
    Kebapcilar L; Taner CE; Kebapcilar AG; Alacacioglu A; Sari I
    Arch Gynecol Obstet; 2010 Jan; 281(1):35-42. PubMed ID: 19330342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyproterone acetate or drospirenone containing combined oral contraceptives plus spironolactone or cyproterone acetate for hirsutism: randomized comparison of three regimens.
    Kelekci KH; Kelekci S; Yengel I; Gul S; Yilmaz B
    J Dermatolog Treat; 2012 Jun; 23(3):177-83. PubMed ID: 21254871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study.
    Guido M; Romualdi D; Giuliani M; Suriano R; Selvaggi L; Apa R; Lanzone A
    J Clin Endocrinol Metab; 2004 Jun; 89(6):2817-23. PubMed ID: 15181063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the clinical efficacy of flutamide and spironolactone plus Diane 35 in the treatment of idiopathic hirsutism: a randomized controlled study.
    Inal MM; Yildirim Y; Taner CE
    Fertil Steril; 2005 Dec; 84(6):1693-7. PubMed ID: 16359967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism.
    Batukan C; Muderris II
    Fertil Steril; 2006 Feb; 85(2):436-40. PubMed ID: 16595223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aromatase gene polymorphism does not influence clinical phenotype and response to oral contraceptive pills in polycystic ovary syndrome women.
    Maier PS; Spritzer PM
    Gynecol Obstet Invest; 2012; 74(2):136-42. PubMed ID: 22889864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic alternatives for the hirsute woman.
    Bassaw B; Maharaj R; Ali A; Roopnarinesingh S
    West Indian Med J; 1992 Mar; 41(1):12-4. PubMed ID: 1533080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polycystic ovary syndrome.
    Al-Inany H
    Clin Evid; 2004 Dec; (12):2678-88. PubMed ID: 15865813
    [No Abstract]   [Full Text] [Related]  

  • 15. Hirsutism--a low dose spironolactone therapy.
    Vĕtr M
    Acta Univ Palacki Olomuc Fac Med; 1989; 122():239-45. PubMed ID: 2530821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
    Teichmann A
    Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of sequential cyproterone acetate/estrogen versus spironolactone/oral contraceptive in the treatment of hirsutism.
    O'Brien RC; Cooper ME; Murray RM; Seeman E; Thomas AK; Jerums G
    J Clin Endocrinol Metab; 1991 May; 72(5):1008-13. PubMed ID: 1827125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyproterone acetate/ethinyl estradiol for acne and hirsutism: time to revise prescribing policy.
    Franks S; Layton A; Glasier A
    Hum Reprod; 2008 Feb; 23(2):231-2. PubMed ID: 18083746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome.
    Fruzzetti F; Perini D; Lazzarini V; Parrini D; Gambacciani M; Genazzani AR
    Fertil Steril; 2010 Oct; 94(5):1793-8. PubMed ID: 19931080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spironolactone for hirsutism in polycystic ovary syndrome.
    Christy NA; Franks AS; Cross LB
    Ann Pharmacother; 2005 Sep; 39(9):1517-21. PubMed ID: 16076921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.